Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003590
Status:
COMPLETED
Last Update Posted:
2016-05-20
First Post:
1999-11-01
Brief Title:
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Study Overview
Official Title:
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma
PURPOSE This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma
Detailed Description:
OBJECTIVES
Determine the partial and complete response rates in patients with unresectable benign meningioma treated with hydroxyurea
Assess the quantitative and qualitative toxic effects of this drug in this patient population
OUTLINE Patients receive oral hydroxyurea twice daily for 2 years in the absence of disease progression or unacceptable toxicity
Patients are followed at 3 months 6 months and then every 6 months for 3 years
PROJECTED ACCRUAL A total of 38 patients will be accrued for this study within 13 months
Determine the partial and complete response rates in patients with unresectable benign meningioma treated with hydroxyurea
Assess the quantitative and qualitative toxic effects of this drug in this patient population
OUTLINE Patients receive oral hydroxyurea twice daily for 2 years in the absence of disease progression or unacceptable toxicity
Patients are followed at 3 months 6 months and then every 6 months for 3 years
PROJECTED ACCRUAL A total of 38 patients will be accrued for this study within 13 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA032102 | NIH | ECOG | httpsreporternihgovquickSearchU10CA032102 |
| S9811 | OTHER | None | None |
| ECOG-S9811 | OTHER | None | None |